Pexidartinib

證據等級: L5

預測適應症: 10 個

Pexidartinib: From Tenosynovial Giant Cell Tumor to HER2 Positive Breast Carcinoma

One-Sentence Summary

Pexidartinib is an oral small-molecule kinase inhibitor targeting CSF1R, KIT, and FLT3-ITD, originally developed for tenosynovial giant cell tumor (TGCT) — this original indication is not captured in the structured drug record but is consistently documented across the literature evidence collected in this pack (e.g., PMID 31602563, 32617868). The TxGNN model’s top-ranked new prediction is HER2 positive breast carcinoma, but this is currently supported by only 1 clinical trial of uncertain relevance and no confirmed literature. Evidence for this specific prediction is weak (L4) and does not yet justify further investment.

Quick Overview

Item	Content
Original Indication	Tenosynovial giant cell tumor (TGCT) — derived from literature evidence in this pack; not present in structured drug/license fields
Predicted New Indication	HER2 positive breast carcinoma
TxGNN Prediction Score	99.98%
Evidence Level	L4
Market Status	✗ Not Marketed
Number of Licenses/NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

The structured original_moa field is marked as a data gap. However, literature evidence collected alongside this candidate (PMID 31602563, “Pexidartinib: First Approval”) describes pexidartinib as an orally administered small-molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 receptor (CSF1R), KIT, and FLT3 with internal tandem duplication (FLT3-ITD). Its established use in TGCT is driven by CSF1 overexpression in that tumor, with pexidartinib blocking CSF1R signaling to reduce tumor-associated macrophage recruitment.

For the predicted new indication, HER2 positive breast carcinoma, the mechanistic rationale is indirect. The evidence pack’s own rationale notes that the proposed link runs through a CSF1R–tumor-associated macrophage (TAM) axis, but HER2-positive breast cancer has no established direct molecular relationship with CSF1R signaling. It is not yet clear whether this represents a genuine biological hypothesis (e.g., targeting the tumor microenvironment as an adjunct to HER2-directed therapy) or simply a knowledge-graph embedding similarity without mechanistic grounding.

Important caveat: within the same evidence pack, several lower-score-ranked candidates — “synovium cancer” (rank 6), “synovium disease” (rank 7), and “malignant giant cell tumor” (rank 10) — are supported by a completed Phase 3 RCT (ENLIVEN, PMID 31229240), long-term follow-up data, and FDA approval. These almost certainly reflect pexidartinib’s already-established indication (TGCT) re-surfacing in the knowledge graph rather than a novel repurposing signal, and should not be treated as new candidates. This is a useful data-quality flag: strong evidence density in this pack correlates with known indication overlap, not necessarily with a validated new use.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01042379	Phase 2	Recruiting	5000	I-SPY2 — a multi-drug adaptive platform trial matching investigational agents to breast cancer subtypes via imaging/biomarker response. It is not confirmed whether pexidartinib is an active treatment arm or specifically linked to the HER2+ subtype (relevance graded C — reasoning: “unconfirmed whether this entry includes a pexidartinib treatment arm or is specifically linked to the HER2+ population; relevance uncertain, requires verification of trial arm design”).

Literature Evidence

Currently no related literature available.

US Market Information

Pexidartinib is currently not marketed in this jurisdiction (market status: Not Marketed; 0 total licenses). No license/NDA records are available to summarize.

Cytotoxicity (Antineoplastic Drugs Only)

Pexidartinib’s established indication (TGCT) is a neoplasm, and the drug is a small-molecule targeted kinase inhibitor, so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (small-molecule tyrosine kinase inhibitor: CSF1R / KIT / FLT3-ITD)
Myelosuppression Risk	Not specified in available data; please refer to the package insert
Emetogenicity Classification	Not specified in available data; please refer to the package insert
Monitoring Items	Liver function parameters (ALT, AST, total bilirubin) — flagged in exposure-response safety literature within this pack (PMID 34585528); please refer to the package insert for the complete monitoring schedule
Handling Protection	Not specified in available data; please refer to institutional handling guidelines for oral antineoplastic agents

Safety Considerations

Please refer to the package insert for safety information. Note that a blocking data gap exists for TFDA-equivalent label warnings/contraindications (DG001), which prevents a formal S1 safety pre-assessment for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link between pexidartinib’s CSF1R/KIT/FLT3-ITD activity and HER2-positive breast carcinoma is indirect and unconfirmed. Supporting evidence is limited to a single trial (I-SPY2) whose relevance to pexidartinib and this specific subtype has not been verified, with no literature support (Evidence Level L4).

To proceed, the following is needed:

Verification of whether pexidartinib is an active treatment arm in NCT01042379 (I-SPY2) and, if so, outcome data specific to the HER2+ cohort
Resolution of the TFDA-equivalent warnings/contraindications data gap (DG001) before any S1 safety pre-assessment
Structured MOA data (DG002) to formally support or refute the CSF1R–TAM–HER2+ breast cancer mechanistic hypothesis
Preclinical evidence establishing a direct or TME-mediated link between CSF1R inhibition and HER2+ breast cancer response
Clarification that TGCT-adjacent labels in this evidence pack (ranks 6, 7, 10) represent the known indication rather than independent repurposing candidates, so they are not mistakenly carried forward as “new” predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.